RxDoctor Payments Data

Krishi Chanduri, MD

Nephrology · Corona, CANPI 1598957540

Payments from drug & device makers

$1,542in general payments, 2019–2025

Across 61 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$421
  • Otsuka America Pharmaceutical, Inc.$370
  • Aurinia Pharma U.S., Inc.$129
  • Johnson & Johnson$116
  • Ardelyx, Inc.$77
  • Sanofi-aventis U.S. LLC$73
  • plus $356 from 11 others

What the payments were for

  • Food & beverage$1,33186%
  • Education$21114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,542 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$86,778
Medicare patients
240
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$67,813
FarxigaDapagliflozin Propanediol46$44,891
LokelmaSodium Zirconium Cyclosilicate44$39,742
KerendiaFinerenone17$24,418
Sevelamer Hcl12$17,654
VeltassaPatiromer Calcium Sorbitex15$17,404
JanuviaSitagliptin Phosphate13$11,887
ProcritEpoetin Alfa18$8,089
Sevelamer Carbonate18$6,822
Calcium Acetate66$4,783
ProsolParenteral Amino Acid 20% No.124$2,934
Tacrolimus13$2,453
Hydralazine Hcl62$1,203
Potassium Chloride21$876
Furosemide106$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$421$84,63390 claims
BayerKerendia$59$24,41817 claims
Johnson & JohnsonProcrit$116$8,08918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.

Other nephrology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →